Somewhere in England right now, a teenager and their family are waiting. They have been waiting, in many cases, for more than five years just to see a specialist. Not for a diagnosis of cancer or a referral for surgery. For someone to talk to about their gender. While they wait, puberty continues. For some of them, that process is a cause of profound, daily distress.

That is what this debate is actually about. Earlier this week, Westminster Hall debated a petition calling for the cancellation of the PATHWAYS clinical trial into puberty blockers for children with gender dysphoria. The trial had already been paused in February after the Medicines and Healthcare products Regulatory Agency raised concerns about the trial design. Many MPs, drawn from Labour, the Conservatives, Reform and the DUP, used the debate not to call for those concerns to be resolved, but to demand the trial be scrapped altogether.

Their arguments were passionate, often sincere, and in some cases carefully researched. They also contained a contradiction so fundamental it deserves to be named plainly.

Many of those MPs, when the Cass review was published in 2024, demanded it be implemented in full. Several cited Hilary Cass’s authority in the debate itself to justify their opposition to the trial. What they appear not to have noticed, or to have chosen to overlook, is that the Cass review explicitly recommended a clinical trial. That trial was meant to be the mechanism for building the evidence base they say is lacking.

A point of precision matters here. Cass did not personally endorse the PATHWAYS design in every detail. But she did recommend a trial, and when the MHRA paused recruitment she said publicly that no new research findings justified the change, and that the decision felt like a response to political pressure rather than science. The scientist those MPs invoke to close down the research is concerned it is being closed down for the wrong reasons. That is not a minor irony. It is the entire argument.

Puberty blockers are not new drugs. They have been used for decades to treat precocious puberty, where children as young as six or seven begin puberty far too early. In those cases, the same drugs, in the same doses, are prescribed to comparable or even younger children, frequently for longer periods of time. Nobody in Westminster Hall called for that use to be reviewed. Nobody described those children as being experimented on.

Some critics will respond that the two situations are ethically different: treating precocious puberty restores a child to a typical developmental pathway, while treating gender dysphoria delays or alters one. But notice what that argument concedes. It concedes that the pharmacology is not the issue. It concedes that the risks are not, in themselves, the reason for opposition. What they are actually doing is making a value judgment about which developmental pathways are legitimate and for which children. That is not a clinical argument. It is a political one.

The asymmetry becomes even harder to defend once you look at the international picture. Several European countries have tightened their protocols in recent years, but even within that shift the response has been towards more careful, more governed use and more research, not prohibition. The United Kingdom is not a beacon of child protection here. It is an increasingly isolated outlier.

Puberty blockers are not disappearing. They have been banned as a treatment on the NHS outside the trial, but a significant number of young people are already obtaining them through private providers or online, outside any regulated clinical framework. No dosage monitoring. No outcome tracking. No safeguarding oversight. Just a prescription and a hope.

The choice is not between puberty blockers and safety. It is between monitored, safeguarded access and unmonitored access with none of those things. Cancellation does not protect children from uncertainty. It simply ensures the uncertainty continues, invisibly, outside any framework anyone can scrutinise.

The MHRA raised concerns about the trial’s control group design and the duration of follow-up. These are genuine methodological questions, but the kind that arise in normal regulatory dialogue, not the kind that indicate the research is misconceived at its root. The MHRA has not said the trial cannot proceed. It has said it needs more answers before it does. That is a different thing entirely.

The Cass review said we need evidence. The PATHWAYS trial is how we get it. You cannot claim to stand with Cass and against the trial at the same time. The logic simply does not hold. And the children who are waiting deserve better than politicians who cannot follow their own argument to its conclusion.

* Tanya Park is a Lib Dem County, Borough & Town councillor in Eastleigh, Hampshire and writes at A Just Society, a liberal policy project making the case for radical progressive policies grounded in liberal principles.